Company Overview
- Website
- novelion.com
- Phone
- (604) 707-7001
- Employees
- 2
- Founded in
- 1981
- Industry
- BioTech/Drugs
- Stock Symbol
- OTCMKTS:NV
- NAICS Codes
-
32 - Manufacturing325 - Chemical Manufacturing3254 - Pharmaceutical and Medicine Manufacturing32541 - Pharmaceutical and Medicine Manufacturing325412 - Pharmaceutical Preparation Manufacturing
- SIC Codes
-
28 - Chemicals and Allied Products283 - Drugs
Financials & Stats
Revenue
$138B
Recent News & Media
Novelion Announces Completion of Plan of Liquidation and Distribution and its Voluntary Dissolution
- Mar 10, 2023
- globenewswire.com
Mati Therapeutics Announces Purchase of Rights From Novelion Therapeutics Inc.
- Feb 1, 2021
- businesswire.com
Delisting of Securities of Stabilis Energy, Inc., Novelion Therapeutics Inc., Revolution Lighting Technologies, Inc., Atlas Financial Holdings, Inc., Approach Resources Inc., the Warrant of Greenland Technologies Holding Corporation, and Nuvectra Corporat
- Nov 27, 2020
- ir.nasdaq.com
Novelion Therapeutics Provides Update on Liquidation Process
- Sep 30, 2020
- globenewswire.com
Novelion Therapeutics Inc.
- Jan 16, 2020
- alvarezandmarsal.com
Novelion Therapeutics Announces Subsidiary Aegerion
- May 20, 2019
- globenewswire.com
Who is Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. The company is privately held and employs 2 people. Novelion Therapeutics focuses on the development of new treatments for rare diseases. Through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., Novelion has a commercialized portfolio which includes MYALEPT® and JUXTAPID®. novelion is also actively developing zuretinol acetate as a potential treatment for inherited retinal disease linked to mutations in RPE65 or LRAT genes. Novelion Therapeutics is dedicated to advancing its portfolio of rare disease therapies through investments in both scientific research and clinical development. You can learn more about Novelion Therapeutics and its work at novelion.com.